Safety, tolerability and clinical implementation of 'ready-to-use' 68gallium-DOTA0-Tyr3-octreotide (68Ga-DOTATOC) (SomaKIT TOC) for injection in patients diagnosed with gastroenteropancreatic neuroendocrine tumours (GEP-NETs).
Prakash ManoharanAngela LamarcaShaunak NavalkissoorJose CaleroPei San ChanPeter JulyanMaribel SierraMartyn CaplinJuan VallePublished in: ESMO open (2021)
The new ready-to-use preparation of 68Ga-DOTATOC (SomaKIT TOC) for injection was safe and well tolerated. This has led to the world's first (EMA) licensed 68Ga-DOTATOC (SomaKIT TOC) radiopharmaceutical for the utility of PET imaging in patients with NETs. This preparation can be robustly implemented into routine clinical practice.
Keyphrases
- pet ct
- pet imaging
- clinical practice
- positron emission tomography
- end stage renal disease
- newly diagnosed
- ejection fraction
- healthcare
- chronic kidney disease
- primary care
- prognostic factors
- neuroendocrine tumors
- ultrasound guided
- molecularly imprinted
- peritoneal dialysis
- open label
- clinical trial
- computed tomography
- quality improvement
- placebo controlled